10-Q: MSP Recovery Faces Delisting, Deepening Losses, and Liquidity Crisis

MSP Recovery, Inc. reported significantly increased net losses and a critical liquidity shortage, leading to a Nasdaq delisting notice and reliance on a volatile equity purchase agreement.

Summary

• Net loss attributable to MSP Recovery, Inc. increased to $432.6 million for the nine months ended September 30, 2025, from $73.9 million in the prior year.
• Total revenues decreased significantly to $1.6 million for the nine months ended September 30, 2025, from $10.0 million in the prior year.
• The company faces substantial doubt about its ability to continue as a going concern due to recurring losses and extremely limited liquidity, with only $1.8 million unrestricted cash as of September 30, 2025.
• Received a Nasdaq Staff Delisting Determination on October 22, 2025, with trading suspended on October 31, 2025, due to non-compliance with minimum stockholders' equity requirements. A hearing is scheduled for December 11, 2025.
• A 1-for-7 reverse stock split was effected on September 1, 2025.
• The Yorkville SEPA is the sole source of short-term liquidity, with Yorkville agreeing to advance an additional $6.0 million in convertible promissory notes, but the company has sold substantially all currently registered shares and needs to file new registration statements.
• A jury awarded plaintiffs $15.7 million (including interest) against the subsidiary MSP Recovery, LLC in the Menendez Litigation, for which a reserve has been established and a writ of execution issued.
• A potential $55.0 million first lien secured delayed draw term loan facility is non-binding and "highly unlikely" to proceed without material revisions.
• Guaranty obligations increased significantly to $1.29 billion as of September 30, 2025.

Sentiment

Score: 1

Explanation: The company faces severe financial distress, including deepening losses, critical liquidity issues, a Nasdaq delisting, and significant legal judgments, with highly uncertain prospects for future financing and revenue generation.

Positives

• Operating loss slightly improved for the nine months ended September 30, 2025, to $(375.5) million from $(395.0) million in the prior year.
• The Cano Health litigation was settled without expected material financial impact.
• Management believes ongoing SEC and USAO investigations will be resolved without material developments.
• The company's proprietary data analytics platform and algorithms are highlighted as a competitive advantage in identifying recovery opportunities.
• The company's Assignor base has grown from 32 Assignors in 2015 to over 160 Assignors to date.

Negatives

• Net loss attributable to MSP Recovery, Inc. increased by 486% to $432.6 million for the nine months ended September 30, 2025.
• Total revenues decreased by 84% to $1.6 million for the nine months ended September 30, 2025.
• Cash decreased from $12.3 million at December 31, 2024, to $1.8 million at September 30, 2025, with only $2.7 million unrestricted cash as of November 17, 2025.
• Total liabilities increased to $2.4 billion at September 30, 2025, from $2.0 billion at December 31, 2024.
• Stockholders' equity is a deficit of $(844.4) million at September 30, 2025, worsening from $(128.4) million at December 31, 2024.
• The company received a Nasdaq Staff Delisting Determination and its stock was suspended from trading on October 31, 2025.
• The potential $55.0 million financing facility is "highly unlikely" to proceed without material revisions.
• The Working Capital Credit Facility and Operational Collection Floor have no remaining funding capacity.
• A $15.7 million judgment was entered against the subsidiary MSP Recovery, LLC in the Menendez Litigation.
• Deferred cash compensation for the Board of Directors totaling $402,250 remains unpaid.
• The Floor Price for Yorkville Convertible Promissory Notes was successively reduced from $26.25 to $0.50 per share, indicating significant stock price decline.
• The company has sold substantially all shares registered for resale to Yorkville and needs to file new registration statements, with no assurance of timing or occurrence.

Risks

• Substantial doubt about the ability to continue as a going concern due to recurring losses and negative cash flows.
• Risk of delisting from Nasdaq, which could limit stock liquidity, increase volatility, and hinder capital raising.
• Dependence on the Yorkville SEPA as the sole source of short-term liquidity, with no guarantee of future funding or timely registration of additional shares.
• Uncertainty regarding the consummation of the potential $55.0 million financing facility.
• Ongoing SEC and USAO investigations, despite management's belief of no material developments, carry inherent uncertainty.
• The Menendez Litigation resulted in a $15.7 million judgment against a subsidiary, with potential for enforcement actions.
• Shareholder litigation alleging fiduciary-duty breaches and unjust enrichment.
• The Eleventh Circuit ruling on the statute of limitations for MSP Act claims could reduce Paid Value of Potentially Recoverable Claims (PVPRC) by an estimated $10.8 billion.
• Ability to generate future revenue is significantly dependent on factors outside the company's control, including changes to MSP Act laws.
• Termination of data access rights would substantially impair the ability to generate recoveries on assigned claims.
• Inability to recover up-front purchase price or investments in pursuing recoveries would adversely affect profitability.
• Dependence on attracting new Assignors to expand the claims portfolio.
• Risk of changes in courts' willingness to grant judgments, requirements for filing cases, or ability to collect on judgments.
• The estimation of liability under the Tax Receivable Agreement is imprecise and subject to significant assumptions.

Future Outlook

The company faces substantial doubt about its ability to continue as a going concern and is dependent on raising additional funds or generating substantial revenue, the timing and amount of which are uncertain. It relies solely on the Yorkville SEPA for short-term liquidity, but has sold substantially all registered shares and needs to file new registration statements, with no guarantee of future funding. A potential $55.0 million financing facility is "highly unlikely" to proceed without material revisions. The company expects its common stock to trade on the OTCQB Venture Market if delisted from Nasdaq.

Management Comments

• "The Company has concluded that there is substantial doubt about its ability to continue as a going concern."
• "Unless we are successful in raising additional funds through the offering of debt or equity securities, we have concluded it is probable we will be unable to continue to operate as a going concern."
• "Management is taking steps to raise additional funds to address its operating and financial cash requirements to continue operations."
• "There are no assurances the Company will receive the necessary funding or generate revenue necessary to fund operations."
• "The Company believes that the investigations will be resolved without any material developments; however, there can be no assurance as to the outcome or future direction thereof." (referring to SEC/USAO investigations)
• "The Company does not expect the Settlement Agreement [with Cano Health] to have a material impact on its financial condition or results of operations."
• "The defendants intend to vigorously defend their position in the Shareholder Litigation."
• "It is the opinion of the Companys management... that it is not possible to determine the probability of loss or estimate of damages, and therefore, the Company has not established a reserve." (referring to Shareholder Litigation)
• "The Company is evaluating its options with respect to these matters, including potential motions to stay enforcement, seeking appropriate relief from the court, or otherwise resolve the judgment." (referring to Menendez Litigation)

Industry Context

The company operates in the healthcare reimbursement recovery and data analytics sector, focusing on Medicare, Medicaid, and commercial health insurers. It aims to disrupt the "antiquated healthcare reimbursement system" by identifying and recovering improper payments. The total potentially serviceable market is estimated at over $161.5 billion annually, with Medicare and Medicaid expenditures projected to grow. The business model relies heavily on the Medicare Secondary Payer Act (MSP Act), which allows for double damages, but changes to this law or its interpretation (like the 11th Circuit ruling) could significantly impact recoveries. The company differentiates itself by acquiring irrevocable assignments of claims, allowing it to control litigation and pursue broader legal theories than competitors. It is developing platforms like "Chase to Pay" and the "MSP/Palantir Clearinghouse Platform" to improve payment accuracy and resolve liens in near real-time, leveraging AI, NLP, and ML.

Comparison to Industry Standards

• The company states it differs from competitors by receiving recovery rights through irrevocable assignments of claims, assuming risk its competitors do not, and allowing it to pursue additional recoveries under numerous legal theories.
• The company believes it would take any competitor significant time to amass its portfolio of claims rights due to the volume of data and strength of data analytics.
• The company's Recovery Multiple for MSP Laws was 0.86x for the nine months ended September 30, 2025, and 1.32x for the year ended December 31, 2024, indicating varying success in recovering amounts in excess of the Paid Amount.
• The company highlights that primary payers routinely fail to fulfill reporting duties under federal law, with some reporting rates as low as 2%, which the clearinghouse platform aims to address.

Management Changes

Corporate Governance

Legal Proceedings

• SEC Investigation: Initiated August 11, 2022, with subpoenas received March 1, 2023, May 10, 2023, August 16, 2023, June 16, 2025, and July 21, 2025. Focuses on Business Combination, financial results, investor agreements, data analytics, projections, accounting, and asset valuation. Management believes it will be resolved without material developments, but no assurance.
• USAO Grand Jury Investigation: Subpoenas received March 10, 2023, and July 18, 2024. Focuses on proprietary algorithms, stock price drop post-Business Combination, marketing materials, and investment agreements. No target letters issued to company associates.
• Cano Health Litigation: Company sued Cano Health for declaratory relief and anticipatory breach; Cano Health sued company for fraud, breach of contract, tortious interference, and unjust enrichment. Settled on September 8, 2025, with dismissal of all claims. No material financial impact expected.
• Shareholder Litigation: Putative class action filed May 7, 2025, against Lionheart Equities, LLC and certain current/former directors/officers, alleging fiduciary-duty breaches and unjust enrichment. In preliminary stages, no reserve established.
• Menendez Litigation: Jury verdict on August 20, 2025, found subsidiary MSP Recovery, LLC liable for breach of oral contract, awarding $12.7 million in damages and $3.0 million in interest (total $15.7 million). Final judgment entered October 17, 2025. Writ of execution issued November 4, 2025, and motion for injunction to turn over membership certificates filed November 5, 2025. Company established a reserve and is evaluating options.

Related Party Transactions

• Loans from MSP Principals: Unsecured promissory note of $112.8 million to John H. Ruiz and Frank C. Quesada (CEO and CLO), bearing 4% annual interest, maturing June 16, 2026.
• Law Firm Advances/Loan: $36.5 million advanced to Law Firm (owned by John H. Ruiz) for operating expenses, amortized during Q3 2024. A $4.95 million unsecured promissory note from the Law Firm for operational funding, due June 2, 2027, no interest.
• Law Firm Payables/Receivables: $1.2 million payable to Law Firm (Sept 30, 2025) and $0.9 million receivable from Law Firm (Sept 30, 2025).
• MSP Recovery Aviation, LLC: $0.2 million receivable from MSP Aviation (affiliate) and $46.9 thousand payable to MSP Aviation (Sept 30, 2025).
• Funds Held for Other Entities: $19.8 million payable to affiliates (primarily Series MRCS).
• VRM MSP: $94.9 million and $274.0 million in interest expense recorded for VRM Full Return and Virage MTA Amendment for three and nine months ended Sept 30, 2025, respectively.
• Virage Warrants/Restructuring: Term sheet with Virage (Feb 18, 2025) to restructure obligations, including warrant exercise and proxy voting rights to MSP Principals for 51% control.
• Founders Pledge: John H. Ruiz and Frank C. Quesada pledged 11.4 thousand shares to secure payment of CPIA.
• Working Capital Credit Facility Collateral: MSP Principals provided additional collateral (equity interests in an affiliate, mortgage on real property, personal guaranty) for Term Loan B advances, with the company paying $0.1 million in associated costs.

Stakeholder Impact

• Shareholders: Significant dilution risk from Yorkville SEPA conversions, potential delisting from Nasdaq, substantial net losses, and ongoing legal uncertainties could negatively impact share value and liquidity. The 1-for-7 reverse stock split also impacts share count and per-share metrics.
• Employees: The company's "going concern" doubt and liquidity issues could create job insecurity.
• Creditors: The company's limited liquidity and substantial debt (including $1.29 billion in guaranty obligations and $764.6 million in claims financing obligations) pose significant repayment risks. The first lien secured nature of the potential new financing facility would subordinate existing unsecured creditors.
• Assignors: The company's ability to generate recoveries and fulfill contractual obligations to assignors (e.g., 50% of Net Proceeds) is at risk due to financial distress.
• Board of Directors: Deferred compensation remains unpaid, indicating financial strain.

Next Steps

• Attend Nasdaq Delisting Hearings Panel on December 11, 2025, to appeal delisting.
• Evaluate options regarding the Menendez Judgment, including motions to stay enforcement or seeking appropriate relief.
• File additional registration statements with the SEC to register more shares for resale to Yorkville.
• Continue negotiations and due diligence for the potential $55.0 million financing facility, though material revisions are expected.
• Management is taking steps to raise additional funds to address operating and financial cash requirements.
• Continue to pursue recoveries from various parties under rights held through CCRAs.
• Implement new strategies to secure new Assignors and expand the claims portfolio.
• Work to increase the number of Assignors providing daily data outputs for the Chase to Pay platform.

Key Dates

Recommendation

The company is in severe financial distress, evidenced by a substantial net loss increase (486% year-over-year), critically low cash reserves ($1.8 million), and a formal "going concern" warning. The Nasdaq delisting notice and subsequent suspension of trading significantly impair liquidity and investor confidence. While there are ongoing efforts to secure financing, the primary source (Yorkville SEPA) is nearly exhausted and future funding is uncertain, with a proposed $55 million facility deemed "highly unlikely" without major revisions. A $15.7 million legal judgment against a subsidiary further exacerbates the financial strain. The company's business model, while potentially lucrative, has not generated substantial revenue to date, and key performance indicators show a low overall recovery multiple. The combination of deepening losses, severe liquidity constraints, regulatory non-compliance, and significant legal liabilities presents an extremely high-risk profile, making the stock a strong sell.

Keywords

MSP Recovery, MSPR, SEC Filing, 10-Q, Quarterly Report, Financial Results, Going Concern, Nasdaq Delisting, Liquidity Crisis, Reverse Stock Split, Yorkville SEPA, Claims Recovery, Healthcare Analytics, Legal Proceedings, Menendez Litigation, Corporate Governance, Capital Raise, Debt Financing, Shareholder Litigation, Medicare Secondary Payer Act